This was demonstrated by a Phase III clinical trial in patients with advanced BRAF V600E-mutated melanoma, based on the investigation of the safety and efficacy of combination therapy with BRAF and a MEK inhibitors [169,170]. The gene discussed is BRAF; the disease is melanoma.